To further validate these findings, we compared PRDM1 and TCF7 expression in cohorts of patients with chronic lymphocytic leukemia (CLL) treated with autologous CD19 CAR T-cells. The gene discussed is PRDM1; the disease is B-cell chronic lymphocytic leukemia.